Aspirin and clopidogrel/Ticagrelor — Competitive Intelligence Brief

Aspirin and clopidogrel/Ticagrelor (Aspirin and clopidogrel/Ticagrelor) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent. Area: Cardiovascular.

marketed Dual antiplatelet agent COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor) Cardiovascular Small molecule

Target snapshot

Aspirin and clopidogrel/Ticagrelor (Aspirin and clopidogrel/Ticagrelor) — Beijing Neurosurgical Institute. This combination of aspirin and a P2Y12 inhibitor (clopidogrel or ticagrelor) prevents blood clots by inhibiting platelet aggregation through multiple pathways.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aspirin and clopidogrel/Ticagrelor TARGET	Aspirin and clopidogrel/Ticagrelor	Beijing Neurosurgical Institute	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel/ticagrelor)
clopidogrel/abciximab	clopidogrel/abciximab	I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio	marketed	Dual antiplatelet agent (P2Y12 inhibitor + glycoprotein IIb/IIIa inhibitor)	P2Y12 receptor (clopidogrel); glycoprotein IIb/IIIa integrin (abciximab)
Clopidogrel+Aspirin	Clopidogrel+Aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
clopidogrel napadisilate + aspirin	clopidogrel napadisilate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
Acetylsalicylic Acid + clopidogrel	Acetylsalicylic Acid + clopidogrel	Hospital Universitari Vall d'Hebron Research Institute	marketed	Dual antiplatelet agent	Cyclooxygenase-1 (COX-1) and P2Y12 receptor
clopidogrel bisulfate + aspirin	clopidogrel bisulfate + aspirin	Seoul National University Hospital	marketed	Dual antiplatelet agent	P2Y12 receptor (clopidogrel); cyclooxygenase (aspirin)
ASA plus Clopidogrel	ASA plus Clopidogrel	Texas Cardiac Arrhythmia Research Foundation	marketed	Dual antiplatelet agent	COX-1 (aspirin); P2Y12 receptor (clopidogrel)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent class)

1. Seoul National University Hospital · 3 drugs in this class
2. Chinese Academy of Medical Sciences, Fuwai Hospital · 1 drug in this class
3. Hospital Universitari Vall d'Hebron Research Institute · 1 drug in this class
4. Inova Health Care Services · 1 drug in this class
5. Peking University Third Hospital · 1 drug in this class
6. Rigshospitalet, Denmark · 1 drug in this class
7. Texas Cardiac Arrhythmia Research Foundation · 1 drug in this class
8. The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · 1 drug in this class
9. The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class
10. University of Athens · 1 drug in this class